Safety and efficacy of 3% diquafosol ophthalmic solution for soft contact lens-related dry eye.

Safety and efficacy of 3% diquafosol ophthalmic solution for soft contact lens-related dry eye. - Safety and efficacy of diquafosol ophthalmic solution for soft contact lens-related dry eye.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024064

Enrollment

Registered

2016-09-16

Start date

2016-09-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry eye

Interventions

Diquafosol Ophthalmic Solution 3% Artificial tears

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: To have dry eye subjective symptoms in both eye mean Tear break up time is less than 5 sec. or Schirmer I test is less than 5 mm (both eye) To have corneal and conjunctival staining (both eye)

Exclusion criteria

Exclusion criteria: Patients have administration of eye drops for dry eye or steroid eye drops 14 days before start day of this study. Patient with an infection eye disease. Patient has a complication of an eye disease except dry eye. This complication is feared to discourage from evaluation of this study. Patients with allergy to the ingredients used in the present study.

Design outcomes

Primary

Measure	Time frame
Safety Tear breakup time corneal and conjunctival staining subjective symptoms contrast sensitivity	—

Countries

Japan

Contacts

Public ContactYoshiaki Yamada

Santen Pharmaceutical Co., Ltd Japan Medical Affairs Group, Development Management Department, Japan Business

clinical@santen.co.jp06-4802-9604

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026